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Abstract
Background: The purpose of this study was to evaluate a 
combined κ and λ light chain immunofixation (CLIF) as a 
screening tool to detect monoclonal immunoglobulins in 
serum and urine. A secondary aim was to investigate the 
impact on workflow and reagent utilisation of a system-
atic implementation of CLIF in addition to routine protein 
electrophoresis (PE) on all samples.
Methods: Light chain antisera (κ and λ) were mixed in 
a 1:1 ratio and loaded in the same sequence as the PE to 
create a superimposable image.
Results: The CLIF procedure agreed significantly better 
with standard immunofixation procedures in the serum 
and urine. In 33 (22%) new patients and in 114 (15%) 
follow-up patients CLIF detected a band missed by PE 
in serum. In 34 (4.5%) of previously categorised cases 
the monoclonal band was below the detection limit 
of CLIF in serum, but still detectable by conventional 
immunofixation electrophoresis. In one case (0.7%) a 
band in a urine specimen was missed by CLIF compared 
to 70 (49%) missed by PE. After the systematic intro-
duction of CLIF turn-around-times (TATs) and utilisa-
tion of laboratory consumables decreased significantly 
(p < 0.001).
Conclusions: A systematic implementation of CLIF led to 
the detection of monoclonal bands missed by PE with an 
improvement in TATs and a decrease in cost.
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sis; monoclonal gammopathy of uncertain significance 
(MGUS); monoclonal immunoglobulin; myeloma; plasma 
cell proliferative disorder; protein electrophoresis.
*Corresponding author: Carel J. Pretorius, Department of Chemical 
Pathology, Block 7, Floor 3, Herston Hospitals Campus, Herston, 
4029, QLD, Australia, Phone: +617 36460083, Fax: +617 36461392, 
E-mail: carel_pretorius@health.qld.gov.au
Wessel Jenner, Sandra Klingberg, Jill R. Tate and Jacobus 
P.J. Ungerer: Department of Chemical Pathology, Pathology 
Queensland, Brisbane, QLD, Australia
Urs Wilgen and Carel J. Pretorius: Department of Chemical 
Pathology, Pathology Queensland, Brisbane, QLD, Australia; and 
The University of Queensland, Brisbane, QLD, Australia
Introduction
The laboratory contribution to the diagnosis and monitor-
ing of plasma cell proliferative disorders largely depends 
on the electrophoretic demonstration of a monoclonal 
immunoglobulin in serum and/or urine [1, 2]. Protein elec-
trophoresis (PE) separates the constituent proteins accord-
ing to charge with most immunoglobulins migrating to the 
anodal or γ-region on agarose gel or capillary zone elec-
trophoresis. The detection limit for a monoclonal immu-
noglobulin is approximately 1–2 g/L and this depends on 
the background polyclonal immunoglobulins [2]. To dem-
onstrate the monoclonal nature of a band seen on PE an 
immunological technique such as immunofixation elec-
trophoresis (IFE) is required. The latter procedures char-
acterise monoclonal immunoglobulins according to the 
heavy (γ, α, μ, ε or δ) and light (κ or λ) chain composition 
and have detection limits of approximately 100–200 mg/L, 
again depending on the background polyclonal immu-
noglobulin staining [2]. Additional information regard-
ing the monoclonal nature of the disease process can be 
obtained from the relative abundance of free light chains 
in serum [3, 4].
The disease spectrum of the monoclonal gam-
mopathies ranges from the frankly malignant multiple 
myeloma (MM) with gross over production of a monoclo-
nal immunoglobulin to a cryptic presentation such as in 
non-secretory MM or some cases with primary amyloido-
sis (AL) where no detectable monoclonal immunoglobulin 
is demonstrable in serum or urine. The mere presence of 
a monoclonal immunoglobulin is also not diagnostic of 
malignancy as implied by the aptly named monoclonal 
gammopathy of uncertain significance (MGUS) which 
constitutes the majority of newly identified cases with a 
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monoclonal immunoglobulin in serum [5, 6]. Thus the 
detection of small bands below the detection limit of PE 
with an analytically more sensitive technique such as IFE 
is not routinely performed in new patients unless there 
is a specific clinical suspicion of multiple myeloma or a 
related disorder [1, 2, 7].
The response criteria for MM include a quantitative 
assessment of the monoclonal immunoglobulin band size 
in the follow-up assessment and in selected patients IFE 
is mandated when the band is no longer visible on PE to 
categorise complete-, near complete remission and other 
categories [1, 2]. To provide a clinically relevant diagnos-
tic service and to comply with the reporting guidelines 
can result in a complicated laboratory workflow with a 
sequential and reflexive addition of IFE and other tests 
based on the supplied clinical information, findings on 
the initial PE, results of other diagnostic tests and by com-
parison with previous results [2]. To complicate matters 
further screening algorithms based on the supplied clini-
cal information is fraught with danger, given the protean 
manifestations of plasma cell proliferative disorders [3].
The purpose of this study was to evaluate the diagnos-
tic performance of a combined κ and λ light chain immu-
nofixation procedure (CLIF) as a screening tool to detect 
monoclonal immunoglobulins in serum and urine. In 
addition the impact on workflow and reagent utilisation 
was assessed after a systematic implementation in paral-
lel to routine electrophoresis.
Materials and methods
The study was performed in a tertiary referral laboratory that pro-
vides a service to a range of clinicians ranging from primary to ter-
tiary care, including bone marrow transplantation. All samples 
with a PE request on serum or urine during an 8-week period were 
included in the assessment of diagnostic performance and under-
went a CLIF investigation. Our routine protocol for investigating 
patients complied with national guidelines [2]. In patients that were 
followed up with known disease the absence of a previously iden-
tified monoclonal immunoglobulin on PE was confirmed with IFE. 
In new patients IFE was performed to characterise newly identified 
bands and in selected cases where the investigation was specifically 
requested on the basis of a high clinical index of suspicion. The 
protocol complied with local ethical standards and was performed 
according to the World Medical Association Declaration of Helsinki 
regarding ethical conduct.
Protein electrophoresis (PE) and  
immunofixation electrophoresis (IFE)
All PE, IFE and CLIF reagents, equipment and quality control materi-
als were obtained from SEBIA (Cedex, France). Urine samples were 
concentrated up to 80-fold with Minicon CS15 concentrators (Mil-
lipore Ireland Ltd, Cork, Ireland). For the PE gel undiluted serum or 
concentrated urine samples were applied and stained with Amido 
Black. For IFE serum samples were diluted with the Sebia diluent 
according to the manufacturer’s recommendations relative to the 
total globulin result ( > 30 g/L a 1:11, 20–30 g/L a 1:6 and  < 20 g/L a 
1:3 dilution). IFE was performed by applying antisera (γ, α, μ, κ, λ, 
free-κ, free-λ) and when indicated δ and ε followed by an acid violet 
stain. All procedures were performed with fresh samples under rou-
tine examination conditions.
Combined light chain immunofixation (CLIF)
The CLIF antisera reagent was prepared in-house by mixing the 
Sebia κ- (SE4736) and λ (SE4737) light chain antisera in a 1:1 ratio and 
stored at 2–8 °C. Serum and urine samples were loaded as described 
for IFE and the κ+λ-antiserum was applied to all tracks of the gel (20 
µL) after which the gels were processed as for IFE.
The samples were loaded on an IFE gel in the same sequence 
as for the PE to create a superimposable image in order to facilitate 
interpretation (Figure 1).
The adjudication of the PE and CLIF gels were performed by two 
staff members and controlled by a third person when the results are 
entered into the laboratory information system. A retrospective audit 
was systematically conducted after the completion period to resolve 
any discrepancies (WJ, SK, CP). An adjudicated final reference diag-
nosis was based on a review of the clinical case history with incorpo-
ration of the standard IFE and iso-electric focussing results where it 
was performed.
The detection limits of PE, IFE and CLIF were determined by 
serially diluting samples with a characterised monoclonal immuno-
globulin band in Sebia diluent and separately with a pooled normal 
serum to imitate both an immunoparetic and polyclonal background.
Turn-around-time (TAT) and test utilisation
The effect on workflow was assessed by comparing the TAT before 
and after implementation of the CLIF and the reorganised laboratory 
process over two equivalent periods of three calendar months. The 
TAT was obtained from the laboratory information system and based 
on the elapsed time between the initial capture of the request and the 
validation of the electrophoresis report. The PE and IFE consumable 
utilisation was estimated from the electronic stores ordering infor-
mation system. To accommodate for the variability in the number of 
antisera used per individual patient, the utilisation of IFE gels were 
standardised relative to the number of PE gels.
Statistics
Agreements in classification relative to the adjudicated reference 
diagnosis are presented as the 95% confidence interval of the Cohen’s 
κ statistic (κCohen) [8]. The distributions of skewed data were described 
as medians and interquartile ranges and differences between medi-
ans were assessed with the Mann-Whitney procedure. Significance 
testing was performed at the 5% level (p < 0.05).
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Results
A total of 3597 samples were received during the study period 
(male = 1953, female = 1644) and no sample was excluded 
from this analysis. There were 1884 serum and 469 urine 
samples collected from test-naïve patients with no record of 
a previous PE, IFE or FLC request. We received 983 serum 
and 264 urine samples from patients known to have a mono-
clonal immunoglobulin or plasma cell proliferative disorder 
from previous investigations for monitoring purposes.
Figure 1 Protein electrophoresis and combined light chain immunofixation (CLIF).
Panel A is a representative example of a 54-lane Sebia Hydragel protein electrophoresis with the numbering scheme starting at the bottom 
left corner and ending at the top right. Lanes 1–29 were loaded with serum samples and lanes 30–53 with concentrated urine samples (see 
text for details). Lane 54 is occupied by a normal serum control sample. Panel B is a Sebia Hydragel 9 position immunofixation gel loaded 
in the same sequence as panel A and fixed with a mixture of anti-κ and anti-λ antiserum (except for lane 54). The numbering on panel B was 
added post analysis to facilitate interpretation.
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Limit of detection
The detection limit for all methods was a function of the 
background immunoglobulin staining. PE detected a 
band of approximately 0.25 g/L with no background stain-
ing and approximately 0.95 g/L with a polyclonal back-
ground. Both IFE and CLIF were able to detect very faint 
bands of approximately 0.05–0.10 g/L with a clear back-
ground, but with a polyclonal background this decreased 
to approximately 0.25 g/L for IFE and 0.50 g/L for CLIF.
Diagnostic performance
The CLIF procedure detected monoclonal protein bands 
in serum and urine for both naïve and known patient 
groups that were not detected by standard PE. The retro-
spective audit with the benefit of clinical history, IFE and 
iso-electric focussing results allowed us to further assess 
the accuracy of both procedures and in all categories the 
agreement was significantly improved for CLIF over PE 
(Table 1).
Naïve patient serums
The agreement between the adjudicated reference diag-
nosis and CLIF (κCohen 0.85) was significantly improved 
over that of PE (κCohen 0.73). Both PE and CLIF were equally 
prone to identifying faint bands as potentially monoclo-
nal (p = 0.27) and in the vast majority (38 PE; 42 CLIF) of 
these cases multiple small oligoclonal bands could be 
demonstrated with the definitive methods of IFE and 
IEF (Figure  2, example 1). Haemolysis (two cases) and 
fibrinogen (one case, Figure 2, example 2) resulted in 
small bands detected on PE, but not with CLIF. In six CLIF 
cases we concluded that an application artefact was mis-
interpreted as a possible band.
Of the 33 patients missed by PE but detected by CLIF, 
17 had bands in the β-region which typed as follows: seven 
IgAκ, six IgAλ, two IgMκ and two with λ Bence Jones 
Protein. The remainder (16 patients) had small monoclo-
nal immunoglobulin bands in the γ-region  < 1 g/L. Exam-
ples of these trace monoclonal immunoglobulin bands are 
shown in Figure 1, lane 18 and Figure 2, examples 3 and 4. 
In one case a small band in the γ-region was not detected 
by both procedures.
Naïve patient urines
The agreement with the adjudicated reference diagnosis 
of CLIF (κCohen 0.99) was significantly improved over that 
of PE (κCohen 0.49). In one case a trace monoclonal λ-band 
was not detected on CLIF compared to 26 cases where PE 
did not detect a monoclonal immunoglobulin in the urine. 
In one patient with marked proteinuria a candidate band 
detected with PE was not confirmed as monoclonal after 
further investigation.
Known patient serums
CLIF (κCohen 0.90) detected 114 monoclonal immunoglob-
ulin bands that were missed with PE (κCohen 0.66). In 34 
(4.5%) samples a band was detected with IFE, but not with 
CLIF and in the majority (32 cases) we concluded that a 
trace monoclonal immunoglobulin below the CLIF limit 
Table 1 Diagnostic performance of patient classified with PE or CLIF compared to the adjudicated diagnosis (incorporating clinical history, 
immunofixation electrophoresis and iso-electric focussing).
      TP  TN  FP  FN  κ (95% CI)
Naïve patients   Serum  CLIF   149  1686a  48  1  0.85 (0.80–0.89)
    PE   116  1693a  41  34  0.73 (0.68–0.79)
  Urine   CLIF   40  428  0  1  0.99 (0.96–1.00)
    PE   14  428  1  26  0.49 (0.30–0.67)
Known patients  Serum  CLIF   722b  223  4  34  0.90 (0.86–0.93
    PE   608b  227  0  148  0.66 (0.60–0.71)
  Urine   CLIF   101  154  5  1  0.95 (0.91–0.99)
    PE   56  158  1  46  0.59 (0.48–0.68)
CLIF, combined light chain immunofixation; FN, false negative; FP, false positive; naïve, no record of previous monoclonal immunoglobulin; 
known, previously detected monoclonal immunoglobulin or known to have a plasma cell proliferative disorder; PE, protein electrophoresis; 
TN, true negative; TP, true positive. aIFE not performed in all cases (only when specifically requested based on clinical suspicion); bIFE was 
not performed if a band visible on PE corresponded to a previously characterised band.
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of detection was present. One patient had a monoclonal 
IgAκ immunoglobulin that reacted poorly with the κ light 
chain sera and in one case the band was detected after 
repeat analysis at a different dilution. In four instances 
oligoclonal banding against a polyclonal background was 
misinterpreted as monoclonal with CLIF.
Known patient urines
PE (κCohen 0.59) missed 46 of the 102 urine monoclonal 
bands while in only one case a small band was missed 
by CLIF (κCohen 0.95). Five cases with a false-positive CLIF 
interpretation were ascribed to a misinterpretation of an 
application artefact.
Turn-around-time and test utilisation 
outcomes
The systematic incorporation of CLIF as part of the initial 
laboratory investigation for all samples resulted in a sig-
nificant TAT reduction of approximately 28  h in all cat-
egories (Table 2). This occurred despite the increase in 
patient workload of 32% which was consistent with the 
Figure 2 Selected examples of findings on protein electrophoresis 
and combined light chain immunofixation (CLIF).
Panels A and C are examples of serum protein electrophoresis (PE) 
with panels B and D the superimposable CLIF results. 1: An example 
of a false positive on both PE and CLIF due to faint oligoclonal 
banding in the γ-region that was fully characterised with routine 
immunofixation electrophoresis (IFE) and isoelectric focussing. 
2: A fibrinogen band visible in the β-γ region on PE, but not detected 
with CLIF. 3: A trace monoclonal IgG λ-band detected by CLIF and 
subsequently confirmed on IFE. 4: An IgAκ band detected in the 
β-region with CLIF, but missed with PE.
general increase of test utilisation between the respective 
periods. The improvement in TAT were due to a number of 
factors the most significant of which was the earlier finali-
sation of reports in known patients where a monoclonal 
band corresponding to one previously typed was present 
– approximately 45% of urine and 16% of serum sequen-
tial IFE procedures were eliminated in this category of 
patients. Second in new patients the confident identifi-
cation of bands, especially in urine and the serum non-
γ-region, allowed quicker finalisation of negative results. 
Third IFE results on newly identified bands and on follow-
up cases were available earlier due to a reduction in total 
IFE workload.
The utilisation of IFE consumables, which are 
required for both the IFE and CLIF procedures, declined 
by 17% compared to PE consumables. This occurred 
despite the fact that every sample received a CLIF proce-
dure. We ascribed this to the reduction in IFE procedures 
performed, especially in known patients, accompanied by 
increased efficiency of CLIF with 54 patients per gel.
Discussion
A novel finding of our study was that the systematic appli-
cation of CLIF with a superimposable image complemen-
tary to routine electrophoresis improved the workflow, 
reduced TATs and decreased the use of total IFE consuma-
bles in our environment. The reduction of IFE procedures 
to confirm the presence of a previously characterised 
monoclonal immunoglobulin band and the avoidance of 
further investigations in new patients without a strong 
clinical indication were the major contributors to this 
finding. In the group of 983 patients followed up with 
a known monoclonal immunoglobulin in serum, CLIF 
detected 114 patients that were missed by PE. According 
to standard protocols this group of patients would have 
Table 2 The effect of CLIF implementation on the turn-around-time 
(TAT) and the utilisation of immunofixation electrophoresis (IFE) 
consumables.
  Pre implementation   Post implementation
Serum samples, n   3484   4548
Urine samples, n   641   860
Serum TAT, ha   94.6 (50.7–118.5)b   62.3 (29.6–95.6)
Urine TAT, ha   118.5 (90.7–141.3)b   92.5 (57.8–120.3)
IFE utilisationc   2.64b   2.19
aMedian (interquartile range); bp < 0.001 compared to the post imple-
mentation period; cUtilisation expressed as the number of IFE gels 
relative to the PE gels.
Brought to you by | University of Queensland - UQ Library
Authenticated
Download Date | 9/21/15 2:58 AM
986      Jenner et al.: Combined κ and λ light chain immunofixation
required at least a subsequent IFE to assist in classify-
ing the therapeutic response [1, 2]. The reduction in IFE 
procedures in this patient group after implementation of 
CLIF partially explained the improved TATs and decreased 
usage of IFE consumables.
The ability to detect serum monoclonal bands migrat-
ing in the α- and β-regions and the knowledge that bands 
below the usual PE detection limit can be confidently 
detected, resulted in decreased sequential and reflexive 
IFE procedures that are time consuming. This had the 
effect of fewer IFE procedures in new patients without 
a strong clinical suspicion of a plasma cell proliferative 
disorder. The systematic implementation of CLIF in par-
allel with PE therefore led to improved workflow in our 
laboratory as evidenced by the improvement in TAT by 
approximately 1 day because the CLIF result was available 
at the time of PE interpretation, which allowed finalisa-
tion of more reports. Even though all samples underwent 
an abbreviated immunofixation, the use of a single lane 
on the IFE gel per sample as opposed to the multiple lanes 
used for routine IFE contributed to the relative reduction 
in IFE consumables.
Second our results demonstrated that CLIF signifi-
cantly improved the detection of monoclonal immuno-
globulin bands over that of conventional PE. This was 
consistent in both serum and urine specimens and in both 
new patients investigated de novo and in known patients 
whose therapeutic responses were monitored. This was 
expected as CLIF is a modified immunofixation procedure 
which has a superior detection limit for monoclonal immu-
noglobulins [1, 2, 7]. Our finding that 22.1% ± 6.7% (95% CI) 
of monoclonal immunoglobulins were not detected with a 
standard PE in the serum of newly investigated patients 
were similar to the report by Eisele et  al. (27.3% ± 6.8%) 
who used a screening immunofixation procedure with 
antisera directed against a mixture of both heavy and 
light chains [7]. Our performance of CLIF in serums of 
known patients and in all the urine samples contributed 
additional information on the analytical performance of a 
screening immunofixation procedure.
The detection limit experiment and the results in 
urine samples demonstrated that in the absence of back-
ground immunoglobulin staining the CLIF procedure per-
forms similarly to IFE. With a polyclonal background the 
detection limits of both CLIF and IFE deteriorate and the 
mixture of both κ and λ signals masks the identification 
of monoclonal bands with CLIF to a greater extent. The 
differential decrease in the detection limits was mostly 
confined to the γ-region and no monoclonal immunoglob-
ulins detected by IFE in the α- or β-regions were missed by 
CLIF. Thus although the performance is an improvement 
over that of PE, IFE still has a role in defining complete 
response in known patients as well as the initial investiga-
tion of selected new patients with a high index of clinical 
suspicion. Standard IFE will still be required to further 
characterise the heavy and light chain composition of new 
patients identified with CLIF.
The importance of not relying on PE alone when 
investigating for Bence Jones proteinuria was reinforced 
by our findings as approximately 49% of monoclonal 
immunoglobulin bands in urine would be missed unless 
some form of immunofixation was performed (Figure 1 
lanes 30–53). In our opinion the only utility of PE in urine 
is to assist in the quantification of the monoclonal fraction 
excreted in timed urine specimens when a band is visible. 
The comparable performance of CLIF and IFE in urine, 
with only one case in 142 (0.7%) missed by CLIF, can be 
ascribed to the low background immunoglobulin staining 
which optimises the analytical sensitivity in this matrix.
The detection of 33 additional small monoclonal 
immunoglobulin bands with CLIF in the serums of naïve 
patients was expected, especially when the monoclonal 
proteins were migrating in the β-region [7]. Although sat-
isfying from a laboratory point of view, the clinical benefit 
of detecting small monoclonal bands especially in the 
γ-region in these patients is not a foregone conclusion as 
the majority of these patients may end with a MGUS diag-
nosis and we may inadvertently have contributed to the 
Ulysses syndrome in some [9]. Due to the short duration 
of this study we did not investigate the clinical outcomes 
of patients in whom small monoclonal immunoglobu-
lins were detected as these may only be settled after a 
number of years and will require a lengthy prospective 
study [7]. If we accept the premise that the detection of 
small monoclonal immunoglobulin bands are of clinical 
benefit, 22.1% of monoclonal immunoglobulins would 
have been missed by PE alone in naïve patients (p < 0.001) 
with approximately one additional patient detected per 57 
tests performed in this patient group.
We considered performing PE in a sequential 
manner and only for the quantitation of bands detected 
with CLIF and IFE, since the contribution of PE in the 
redesigned process was largely limited to this purpose. 
We have not pursued this avenue further because mod-
elling suggested that a major portion of the improved 
TAT of the new process would be sacrificed by a sequen-
tial process. Second the potential reduction in PE con-
sumables will be offset by an increase in manual labour 
due to sample retrieval and setup. Although not a major 
consideration a potential risk of relying only on CLIF in 
new patients is that cases with heavy chain disease may 
be missed.
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Limitations
A limitation of this study is the lack of IFE investigations 
in all naïve patients in whom no band was detected with a 
resultant overestimation of the diagnostic performance of 
CLIF. In known patients 4.5% of monoclonal bands were 
below the detection limit of CLIF and we therefore esti-
mate that approximately eight small bands may have been 
missed by CLIF of which we detected one which had an IFE 
performed due to clinical suspicion. It would, however, be 
impractical to perform IFE on every sample received for 
PE and this is also not the current standard of care [2, 7]. 
In addition we did not perform IFE on follow-up samples 
where the monoclonal immunoglobulin detected on PE 
corresponded to a previously characterised band; this is, 
however, not expected to have a significant influence on 
our findings. Lastly one should be careful to extrapolate 
our findings to other settings with a different clinical case 
mixture. The impact on workflow and consumable utilisa-
tion will depend on local laboratory practice and the ratio 
of new and follow-up patients.
In summary, a systematic implementation of CLIF in 
parallel to PE allowed improved detection of monoclonal 
immunoglobulins and improved our workflow with a 
reduction in TAT and usage of IFE consumables. CLIF can 
potentially reduce the number of routine IFE procedures 
in all urines and in serums of monitored patients with 
plasma cell proliferative disorders.
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